Clinical Trials Logo

Chronic Kidney Failure clinical trials

View clinical trials related to Chronic Kidney Failure.

Filter by:

NCT ID: NCT01232257 Completed - Clinical trials for Chronic Kidney Disease

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.

NCT ID: NCT01085552 Completed - Anaemia Clinical Trials

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

Start date: November 2007
Phase: Phase 1
Study type: Interventional

A study to see how a single subcutaneous dose of Epoetin beta (NeoRecormon®) in healthy Japanese compares with a single subcutaneous dose of Epoetin beta (NeoRecormon®) in Caucasian Male subjects. Each subject received a single subcutaneous dose of 50IU/kg of NeoRecormon Multidose solution on Day 1.

NCT ID: NCT01083186 Completed - Clinical trials for Secondary Hyperparathyroidism

Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience

PROTECT
Start date: June 2009
Phase: N/A
Study type: Observational

The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.

NCT ID: NCT01081665 Completed - Clinical trials for Secondary Hyperparathyroidism

Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

Start date: December 2006
Phase: N/A
Study type: Observational

The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.

NCT ID: NCT00951353 Completed - Clinical trials for End Stage Renal Disease

Immune Development in Pediatric Transplantation (IMPACT)

Start date: July 2009
Phase:
Study type: Observational

Transplantation is the preferred method of treatment for end-stage renal disease (ESRD) in children. Over the past forty years, the use of newer immunosuppressive drugs has decreased the risk for organ rejection considerably, and improved short-term outcomes. However, these costly and complicated life-long treatment regimens also cause serious side effects. This has been particularly true for children, who undergo treatment with these drugs at the same time they are transitioning, physically and emotionally, from childhood to adulthood. These factors lead to significantly reduced life-spans, decreased drug regimen adherence, and an increased need for re-transplantation, as compared with adults. Current immunosuppressive procedures and strategies for children mimic those for adults, despite the difference between the two populations' immune systems and needs. New strategies aimed at tailoring to an individual child's needs would both reduce the risk of complications and improve outcomes. The purpose of this study is to generate information which will help to change the current practice of pediatric transplantation into one that is more individualized and preventative.

NCT ID: NCT00806130 Completed - Clinical trials for Chronic Kidney Failure

Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients

Start date: September 2008
Phase:
Study type: Observational

The purpose of this study is to assess health related quality of life and its predictors among chronic dialysis patients and to assess cognitive function using 3 different tests. (undergraduate medical student research project; not published)

NCT ID: NCT00804453 Completed - Clinical trials for Chronic Kidney Failure

Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line

Start date: November 2008
Phase: N/A
Study type: Interventional

The primary objective is to collect data to evaluate the biocompatibility of two types of blood circuit, already on the market.

NCT ID: NCT00794326 Completed - Clinical trials for Chronic Kidney Failure

Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD

PDOne
Start date: October 2008
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the hypertensive peritoneal dialysis patients with aim to decrease hypertension and to improve the sodium/water balance.

NCT ID: NCT00781690 Completed - Clinical trials for Chronic Kidney Failure

Reduction of Heparin Dose in Dialysis With Evodial System

RHODES
Start date: September 2008
Phase: N/A
Study type: Interventional

The current clinical study aims at defining an index of Anti Xa, which is the marker to evaluate the activity of heparin, at the end of the dialysis treatment and so showing the possibility to decrease heparin doses during hemodialysis when using Evodial hemodialyzer. Actually, an elevated value of AntiXa at the end of the dialysis treatment increases the risk of bleeding for patients with diabetic retinopathy, or for instance in case of fall at home.

NCT ID: NCT00760162 Completed - Clinical trials for Chronic Kidney Failure

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure

Probiotics
Start date: August 2007
Phase:
Study type: Observational

The bowel can serve as a complement to the kidneys' excretory function A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been called "enteric dialysis"® Confirm the alleviation of uremic syndrome hypothesis Determine the outcome of probiotics treatment Confirm U.S. FDA's Generally Recognized As Safe (GRAS) status - if needed